Clinical Trial Update: ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of ZGN-440 (Beloranib) for obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Beloranib (Beloranib)

Snippet

Sponsor: Zafgen, Inc. | Conditions: Obesity | Phase 1 | Status: COMPLETED